Acepodia, Inc. (TPEX:6976)

Market Cap	7.75B -26.3%
Revenue (ttm)	n/a -56.7%
Net Income	-828.06M
EPS	-1.42
Shares Out	582.87M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	347,550
Open	13.35
Previous Close	13.30
Day's Range	12.15 - 13.35
52-Week Range	10.85 - 18.60
Beta	0.51
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2026

About Acepodia

Acepodia, Inc. operates as a clinical stage biotechnology company. The company engages in developing cell therapies with its antibody cell conjugation (ACC) platform technology to address cancer care. It develops AD2C targeting GPC3 for HCC which is in preclinical stage; ACE 1831 targeting CD20 that is in phase 1 clinical trial; The company is based in Grand Cayman, the Cayman Islands.

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Shih-Chia Hsiao
• Country: Cayman Islands
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6976

Financial Performance

In 2025, Acepodia's revenue was 185,000, a decrease of -56.67% compared to the previous year's 427,000. Losses were -754.40 million, 51.9% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 8, 2026

Data Sources Report a data error